secwatch.observer — SEC 8-K summary
======================================

Issuer:     Pasithea Therapeutics Corp. (KTTA)
CIK:        0001841330
Form:       8-K
Filed at:   2026-05-04T23:59:59+00:00
Accession:  0001213900-26-051681
Event type: leadership
Sentiment:  neutral
Materiality: 0.55
Item codes: 5.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Pasithea Therapeutics appoints Kartik Krishnan as Chief Medical Officer, effective May 1, 2026
--------------------------------------------------------------------------------

- Dr. Krishnan appointed CMO effective May 1; will lead PAS-004 clinical strategy for NF1-associated neurofibromas.
- Over 20 years of experience; previously CMO at Arcus Biosciences, contributed to cobimetinib approval for melanoma.
- Employment agreement: $500k base salary, 40% bonus eligibility, and options for 1.13M shares at $0.841 exercise price.
- CEO Tiago Reis Marques granted options for 1.76M shares; other execs/employees received 1.24M shares in aggregate.
- Non-employee directors each receive options for 152,783 shares, vesting over one year.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1841330/000121390026051681/0001213900-26-051681-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1841330/000121390026051681/ea0288864-8k_pasithea.htm
  HTML page:      https://secwatch.observer/filing/0001213900-26-051681

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer